囊性纤维化成人患者CT评分系统演变的预测价值
该纵向回顾性研究对64例成人囊性纤维化患者间隔中位3.88±1.59年的两次HRCT用Bhalla和Brody II评分,发现Brody II年变化与FEV1%年下降、肺部急性加重及口服抗生素次数显著相关,Bhalla评分与急性加重及口服治疗次数呈中度负相关,两量表观察者间及观察者内一致性很强。
要点
- Brody II评分年变化与FEV1%年下降、急性加重及口服抗生素次数显著相关,可用于临床随访。
- Bhalla评分年变化与急性加重及口服治疗次数呈中度负相关。
- Bhalla和Brody II两量表观察者间及观察者内一致性均很强。
核心结论
- Brody II HRCT评分系统的年演变显示出预测价值,并与FEV1%下降、肺部急性加重及口服抗生素治疗相关。
研究设计与样本
- 纵向回顾性研究,纳入64例成人囊性纤维化患者,由两名资深放射科医师对两次连续HRCT分别用Bhalla和Brody II评分量表评分。
- 两次HRCT间隔中位3.88±1.59年,计算各量表年评分变化并与年FEV1%下降、肺部急性加重及抗生素治疗次数进行相关性分析。
关键影像表现/征象
- 两次HRCT的Bhalla和Brody II年评分变化均为正值,提示结构情况随时间恶化。
- 肺功能显示动态肺容积低于一般人群,总体上呼吸功能随时间恶化。
诊断标准与关键数值
- 使用Bhalla和Brody II两种HRCT评分量表,由两名资深放射科医师评分。
- Brody II量表年变化与年FEV1%下降、急性加重及口服抗生素治疗次数呈显著统计学相关。
- Bhalla量表与急性加重及口服治疗次数呈中度负相关。
- 年FEV1%变化与急性加重或抗生素治疗次数之间未发现统计学显著关系。
- 两量表观察者间和观察者内一致性均很强。
临床应用与阅片要点
- 原文结论认为Brody II评分的年演变对临床随访有用。
- 阅片时可关注Brody II评分的年变化,因其与FEV1%下降、急性加重及口服抗生素治疗次数相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess whether the evolution of two consecutive high-resolution computed tomography (HRCT) scores in patients with cystic fibrosis (CF) has prognostic value.
METHODS: A longitudinal retrospective study was performed to research adult patients with CF. Two consecutive HRCT studies were scored using Bhalla and Brody II scoring scales by two senior radiologists. Annual scoring changes for each scale were calculated and correlated with annual FEV1% decline, with pulmonary exacerbations and number of antibiotic treatments.
RESULTS: We selected sixty-four adult patients. The median interval between the two HRCTs was 3.88 ± 1.59 years. The mean spirometric values showed dynamic lung volumes lower than the general population; globally, there was a worsening of respiratory function over time. The change in the annual HRCT scores was positive on both scales, indicating a worse structural situation over time. The Brody II scale annual change showed a significant statistical correlation with a decline in the annual FEV1%, exacerbations and number of oral antibiotic treatments. In contrast, for the Bhalla scale, the relationship was moderately inverse with exacerbations and with the number of oral treatments. No statistically significant relationships were found for the change in the annual FEV1% and exacerbations or number of antibiotic treatments. The interobservational and intraobservational agreements were very strong in both scales.
CONCLUSIONS: The annual evolution of the Brody II HRCT scoring system demonstrated a predictive value and correlated with FEV1% decline, pulmonary exacerbations and oral antibiotic treatments.
KEY POINTS: • HRCT evolution has prognostic value in cystic fibrosis. • Temporal evolution for the Brody II score is useful for clinical follow-up. • Brody II score changes correlate with FEV1% decline, pulmonary exacerbations and number of antibiotic treatments.
引用
- Zorzo C, Caballero P, Diab L, et al. Predictive value of computed tomography scoring systems evolution in adults with cystic fibrosis. Eur Radiol. 2020. PMID: 32128619. doi:10.1007/s00330-020-06759-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。